Adenosine kinase inhibitor compounds, pharmaceutical composition, and uses thereof
Pyrazolo[4,3-d]pyrimidine-derived compounds act as potent adenosine kinase inhibitors, addressing the limitations of current ASD therapies by increasing adenosine levels and improving behavioral and cognitive symptoms in an ASD animal model.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- CENT NACIONAL DE PESQUISA EM ENERGIA E MATERIAIS
- Filing Date
- 2025-12-12
- Publication Date
- 2026-06-18
AI Technical Summary
Current therapies for autism spectrum disorder (ASD) are resource-intensive and have uncertain benefits, with significant adverse effects, while existing pharmacological interventions lack disease-modifying therapies, and adenosine kinase (ADK) inhibition offers a potential therapeutic strategy.
Development of pyrazolo[4,3-d]pyrimidine-derived compounds that act as potent adenosine kinase inhibitors, increasing adenosine concentrations in the brain and other organs, thereby modulating neurotransmission and alleviating ASD symptoms.
The compounds effectively restore normal sociability, cognitive performance, and reduce repetitive behaviors in an animal model of ASD, with favorable pharmacokinetic properties and metabolic stability, suggesting a promising therapeutic approach for ASD.
Smart Images
Figure IMGF000011_0001 
Figure IMGF000012_0001 
Figure IMGF000013_0001